December 2020 FDA Recall Drug by Imprimis Njof, Llc
D-0177-2021 - Lack of assurance of sterility

This Class II drug recall was voluntarily initiated by Imprimis Njof, Llc on December 17, 2020 for the product Drug. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0177-2021

Reason for Recall
Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.
Initiated
12-17-2020
Reported
01-06-2021
Quantity
6520 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979

Batch or Lot Expiration Information

Lot# : 20JUN010, Exp 5/12/21